semaglutide news 2025 Market Size, Share & Trends Report, 2025-2035 GLP-1 use growing fastest among

How long do weight loss jabs take to work

The most frequently reported issues include: Nausea : 21.49% of patients Diarrhea : 10.62% Vomiting : 9.10% Dyspepsia (indigestion) : 8.67% Constipation : 7.92% Decreased appetite : 5.49% While many tolerate these medications well, over 10% of patients stop or interrupt treatment due to severe discomfort

Tirzepatide also activates the GIP receptor, potentially giving it an edge in effectiveness

Results from the cardiovascular outcomes trial with liraglutide in patients with type 2 diabetes mellitus (LEADER) indicate liraglutide treatment is associated with a statistically significant reduction in cardiovascular risk (assessed using a composite outcome (first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke during the 3.55 year trial period))